Samsung Bioepis’ Thomas Newcomer explains the reasons why biosimilar developers are or are not feeling confident about the consistency of the US market in the coming years.
Thomas Newcomer
Advertisement
Thomas Newcomer is senior vice president and head of US commercial
Samsung Bioepis.
Articles by Thomas Newcomer
The IRA and MFN are affecting decisions made all throughout the entire drug development process.
Thomas Newcomer of Samsung Bioepis discusses how certain classes of drugs don’t have enough biosimilars in development and the impact that this can have in the coming years.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly Releases Updated Safety Data for Foundayo Following FDA’s Request
2
Johnson & Johnson’s Experience Navigating The Commissioner’s National Priority Voucher Program
3
How AI Is Transforming Drug Labeling
4
FDA’s Shift Signals a New Era for Data-Driven Drug Development
5